Functionally, PRMT1 promotes tumor growth and confers CBP resistance across multiple preclinical models, including HNSCC cell lines, CDX, PDO, PDX, and Prmt1cKO mouse models, suggesting that targeting PRMT1 in combination with CBP could be a promising therapeutic strategy. This evidence concerns the gene PRMT1 and neoplasm.